We are delighted to congratulate our client Hummingbird Bioscience on the successful out-licensing of multi-payload antibody-drug conjugate (ADC) technology and related intellectual property and assets, exclusively for use in the field of oncology, to Callio Therapeutics.
Callio Therapeutics has secured US$187 million in its Series A financing, led by Frazier Life Sciences and joined by a global syndicate of top life science investors. Callio Therapeutics is focusing on advancing its HER2-targeted dual-payload ADC through clinical proof-of-concept, and progressing its other assets.
Led by Adam Gregory and Robert Watson, a Mewburn Ellis LLP team worked with the IP team at Hummingbird Bioscience to devise and execute the strategy behind the IP position that now forms a key part of the foundation of Callio Therapeutics.
We extend our heartfelt congratulations to the teams at Hummingbird Bioscience and Callio Therapeutics, and look forward to their continued success in developing innovative therapeutics.
